Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.37 |
| ▸ | PPARD | Q03181 | 11/20 | 0.37 |
| ▸ | PPARA | Q07869 | 14/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380241 | 1.00 | PPARG (0.37) | PPARGPPARDPPARAKDM4EL3MBTL1 | |
| SCHEMBL4381987 | 0.91 | PPARA (0.41) | PPARGPPARDPPARAKDM4EL3MBTL1 | |
| SCHEMBL4475020 | 0.91 | PPARA (0.41) | PPARGPPARDPPARAKDM4EL3MBTL1 | |
| SCHEMBL13867832 | 0.90 | PPARA (0.36) | PPARGPPARDPPARAKDM4EL3MBTL1 | |
| SCHEMBL4377325 | 0.84 | PPARA (0.39) | PPARGPPARDPPARAIKBKB | |
| SCHEMBL4478212 | 0.84 | PPARA (0.39) | PPARGPPARDPPARAIKBKB | |
| SCHEMBL14281494 | 0.83 | PPARG (0.41) | PPARGPPARDPPARAKDM4E | |
| SCHEMBL4466949 | 0.82 | PPARD (0.35) | PPARGPPARDPPARAKDM4EL3MBTL1 | |
| SCHEMBL14281500 | 0.82 | PPARA (0.43) | PPARGPPARDPPARAKDM4E | |
| SCHEMBL4478526 | 0.81 | PPARA (0.41) | PPARGPPARDPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538131-B2 | 2-{-3-′2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197612-A1 | 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | PPARA, PPARG, PPARD | PPARG 2/4885PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.